Antenatal Corticosteroids Trial

Antenatal Corticosteroids Trial. This major international randomized controlled trial was a pivotal study investigating the administration of corticosteroids to pregnant women at risk of preterm birth in low-resource settings. Coordinated by the World Health Organization and partners like the Eunice Kennedy Shriver National Institute of Child Health and Human Development, it sought to determine if the established benefits seen in high-income countries translated to regions with high neonatal mortality. The trial's findings, published in The New England Journal of Medicine, significantly influenced global health policy and sparked important debates in obstetrics.

Background and Rationale

The use of antenatal corticosteroids, primarily betamethasone and dexamethasone, was pioneered following landmark research by Sir Graham Liggins and Ross Howie in the 1970s. Their work, conducted in New Zealand, demonstrated that these drugs accelerated fetal lung maturation, reducing the incidence of respiratory distress syndrome in premature infants. This therapy became a cornerstone of neonatal intensive care in developed nations, endorsed by bodies like the American College of Obstetricians and Gynecologists and the Royal College of Obstetricians and Gynaecologists. However, its efficacy and safety had not been rigorously evaluated in low and middle-income countries, where the burden of preterm birth complications is highest and health systems, including access to neonatal resuscitation and surfactant therapy, differ substantially. The World Health Organization therefore prioritized this trial to address a critical evidence gap in maternal health and child survival strategies.

Trial Design and Participants

The trial was a multi-country, community-based, randomized controlled trial with a placebo-controlled design. It was conducted across 29 sites in six countries: Argentina, Guatemala, India, Kenya, Pakistan, and Zambia. Pregnant women between 26 and 34 weeks of gestation, identified as at high risk of imminent preterm birth, were enrolled. Participants were randomly assigned to receive a course of either betamethasone or a matching placebo. The primary outcomes measured were neonatal death, stillbirth, and the incidence of possible maternal bacterial infection. The study design emphasized practical delivery within existing primary health care systems, often involving community health workers and midwives in identification and follow-up, reflecting the realities of the Global South.

Key Findings and Outcomes

Contrary to expectations from high-income settings, the trial found no significant reduction in the primary outcome of neonatal death among infants whose mothers received betamethasone. Furthermore, the results indicated a statistically significant increase in the risk of possible maternal bacterial infection in the corticosteroid group. There was also a concerning, though not statistically definitive, signal of increased neonatal death in a subgroup of infants born at or after 37 weeks of gestation, raising questions about the timing of administration. These findings, presented at forums like the Society for Maternal-Fetal Medicine and published in The New England Journal of Medicine, challenged the assumption that this intervention was universally beneficial without robust system support.

Impact on Clinical Practice

The immediate impact was a major revision of the World Health Organization's global guidelines on managing preterm birth. The organization issued a conditional recommendation, advising that antenatal corticosteroids only be provided in settings where adequate antenatal care, accurate gestational age dating, and access to preterm birth management and neonatal intensive care are assured. This prompted national ministries of health, such as those in Kenya and India, to re-evaluate their implementation programs. The trial underscored the critical principle that effective interventions in tertiary care hospitals in Europe or North America may not yield the same results when translated to community health settings without necessary infrastructure, a key lesson for implementation science.

Controversies and Subsequent Research

The trial's results generated considerable debate within the obstetrics and global health communities. Some experts from institutions like Johns Hopkins University and the University of Oxford raised methodological concerns, including the use of clinical diagnosis for maternal infection and the challenges of precise gestational age assessment in the trial settings. In response, further research was initiated, including the WHO ACTION-I trial, which specifically evaluated dexamethasone in hospital settings in similar countries. Other studies, such as those led by the Global Alliance to Prevent Prematurity and Stillbirth, continue to investigate optimized delivery strategies. The controversy highlighted the complexities of evidence-based medicine across diverse health systems and reinforced the need for context-specific research rather than direct extrapolation from trials conducted in high-income countries.

Category:Medical trials Category:Obstetrics Category:World Health Organization